Andrew Mujugira1,2, Connie Celum1,2,3, Jordan W Tappero4, Allan Ronald5, Nelly Mugo1,6, Jared M Baeten1,2,3. 1. 1 Department of Global Health, University of Washington , Seattle, Washington. 2. 2 Department of Epidemiology, University of Washington , Seattle, Washington. 3. 3 Department of Medicine, University of Washington , Seattle, Washington. 4. 4 Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention , Atlanta, Georgia . 5. 5 Departments of Medicine and Medical Microbiology, University of Manitoba , Winnipeg, Canada . 6. 6 Center for Clinical Research, Kenya Medical Research Institute , Nairobi, Kenya .
Abstract
BACKGROUND: Antiretroviral therapy (ART) markedly reduces the risk of HIV-1 transmission in serodiscordant partnerships. We previously found that younger age and higher CD4 counts were associated with delayed initiation of ART by HIV-1-infected partners in serodiscordant partnerships. Among those initiating ART, we sought to explore whether those same factors were associated with failure to achieve viral suppression. METHODS: In a prospective study of HIV-1-infected persons who had a known heterosexual HIV-1-uninfected partner in Kenya and Uganda [Partners Pre-Exposure Prophylaxis (PrEP) Study], we used Cox proportional hazards regression to evaluate correlates of viral nonsuppression (HIV-1 RNA >80 copies/ml). RESULTS: Of 1,035 HIV-1-infected participants initiating ART, 867 (84%) achieved viral suppression: 77% by 6 months and 86% by 12 months. Younger age [adjusted hazard ratio (aHR) 1.05 for every 5 years younger; p = .006], lower pretreatment CD4 count (aHR 1.26; p = .009 for ≤250 compared with >250 cells/μl), and higher pretreatment HIV-1 RNA quantity (aHR 1.21 per log10; p < .001) independently predicted failure to achieve viral suppression. Following initial viral suppression, 8.8% (76/867) experienced virologic rebound (HIV-1 RNA >200 copies/ml): 6.3% and 11.5% by 6 and 12 months after initial suppression, respectively. Age was the only factor associated with increased risk of virologic rebound (aHR 1.33 for every 5 years younger; p = .005). CONCLUSIONS: For HIV-1-infected persons in serodiscordant couples, younger age was associated with delayed ART initiation, failure to achieve viral suppression, and increased risk of virologic rebound. Motivating ART initiation and early adherence is a key to achieving and sustaining viral suppression.
BACKGROUND: Antiretroviral therapy (ART) markedly reduces the risk of HIV-1 transmission in serodiscordant partnerships. We previously found that younger age and higher CD4 counts were associated with delayed initiation of ART by HIV-1-infected partners in serodiscordant partnerships. Among those initiating ART, we sought to explore whether those same factors were associated with failure to achieve viral suppression. METHODS: In a prospective study of HIV-1-infectedpersons who had a known heterosexual HIV-1-uninfected partner in Kenya and Uganda [Partners Pre-Exposure Prophylaxis (PrEP) Study], we used Cox proportional hazards regression to evaluate correlates of viral nonsuppression (HIV-1 RNA >80 copies/ml). RESULTS: Of 1,035 HIV-1-infectedparticipants initiating ART, 867 (84%) achieved viral suppression: 77% by 6 months and 86% by 12 months. Younger age [adjusted hazard ratio (aHR) 1.05 for every 5 years younger; p = .006], lower pretreatment CD4 count (aHR 1.26; p = .009 for ≤250 compared with >250 cells/μl), and higher pretreatment HIV-1 RNA quantity (aHR 1.21 per log10; p < .001) independently predicted failure to achieve viral suppression. Following initial viral suppression, 8.8% (76/867) experienced virologic rebound (HIV-1 RNA >200 copies/ml): 6.3% and 11.5% by 6 and 12 months after initial suppression, respectively. Age was the only factor associated with increased risk of virologic rebound (aHR 1.33 for every 5 years younger; p = .005). CONCLUSIONS: For HIV-1-infectedpersons in serodiscordant couples, younger age was associated with delayed ART initiation, failure to achieve viral suppression, and increased risk of virologic rebound. Motivating ART initiation and early adherence is a key to achieving and sustaining viral suppression.
Authors: Scott E Hadland; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; Robert S Hogg; Julio S Montaner; Evan Wood Journal: AIDS Patient Care STDS Date: 2012-03-19 Impact factor: 5.078
Authors: Brandon L Guthrie; Robert Y Choi; Amy Y Liu; Romel D Mackelprang; Anne F Rositch; Rose Bosire; Lucy Manyara; Ann Gatuguta; James N Kiarie; Carey Farquhar Journal: J Acquir Immune Defic Syndr Date: 2011-11-01 Impact factor: 3.731
Authors: L F Brigido; R Rodrigues; J Casseb; D Oliveira; M Rossetti; P Menezes; A J Duarte Journal: AIDS Patient Care STDS Date: 2001-11 Impact factor: 5.078
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Moses R Kamya; Harriet Mayanja-Kizza; Andrew Kambugu; Sabrina Bakeera-Kitaka; Fred Semitala; Patricia Mwebaze-Songa; Barbara Castelnuovo; Petra Schaefer; Lisa A Spacek; Anne F Gasasira; Elly Katabira; Robert Colebunders; Thomas C Quinn; Allan Ronald; David L Thomas; Adeodata Kekitiinwa Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Susan H Eshleman; Ethan A Wilson; Xinyi C Zhang; San-San Ou; Estelle Piwowar-Manning; Joseph J Eron; Marybeth McCauley; Theresa Gamble; Joel E Gallant; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Ben Kalonga; Jose H Pilotto; Beatriz Grinsztejn; Sheela V Godbole; Nuntisa Chotirosniramit; Breno Riegel Santos; Emily Shava; Lisa A Mills; Ravindre Panchia; Noluthando Mwelase; Kenneth H Mayer; Ying Q Chen; Myron S Cohen; Jessica M Fogel Journal: HIV Clin Trials Date: 2017-04-07
Authors: Putu Duff; Kate Shannon; Melissa Braschel; Flo Ranville; Mary Kestler; Ruth Elwood Martin; Andrea Krüsi; Kathleen Deering Journal: Int J STD AIDS Date: 2020-12-08 Impact factor: 1.359
Authors: Molly A Rosenthal; George Wanje; Barbra A Richardson; Juma Shafi; Lei Wang; Linnet Masese; Danielle N Poole; Walter Jaoko; Jane Simoni; R Scott Mcclelland Journal: AIDS Behav Date: 2021-04-20
Authors: Domonique M Reed; Allahna L Esber; Trevor A Crowell; Kavitha Ganesan; Hannah Kibuuka; Jonah Maswai; John Owuoth; Emmanuel Bahemana; Michael Iroezindu; Julie A Ake; Christina S Polyak Journal: AIDS Res Ther Date: 2021-07-22 Impact factor: 2.250
Authors: Jason A Craw; Linda Beer; Yunfeng Tie; Tom Jaenicke; R Luke Shouse; Joseph Prejean Journal: J Acquir Immune Defic Syndr Date: 2020-06-01 Impact factor: 3.771